Re-appointment of Internal Auditor and Cost Auditor of the Company for the FY 2026-2027.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Fredun Pharmaceuticals reported strong audited results for FY ended March 2026. Standalone revenue grew 40% to Rs 639.12 crore from Rs 456.27 crore, while standalone profit after tax rose 60% to Rs 33.21 crore from Rs 20.81 crore. The Board recommended a final dividend of Rs 0.70 per share (7%) for shareholder approval. Key corporate actions include a 2:1 bonus share issuance and increase in authorised share capital from Rs 10 crore to Rs 50 crore. New auditors appointed for FY 2026-27 include M/s Nikhil Maniar & Associates as Internal Auditor and M/s Joshi Apte & Associates as Cost Auditor. Statutory auditors issued an unmodified opinion. One-time tax adjustments of Rs 54.83 crore (deferred tax and short provisions due to MSME provisions) were noted, with underlying profit at Rs 32.62 crore.
The company delivered robust revenue and profit growth, signaling strong operational performance. The bonus issue and capital increase suggest expansion plans, while dividend signals shareholder returns. Positive audit opinion is reassuring, though investors should note the auditor's concern about delayed IEPF transfers.